Triamcinolone acetonide dissolving microneedle patch for hypertrophic scar or keloid triamcinolone acetonide, dissolving microneedle patch, hypertrophic scar, keloid
Conditions
Interventions
Each participant was given two equal parts of the hypertrophic scar or keloid then one side of the scar
was randomized for treatment with triamcinolone dissolving microneedle patch and the other side
Treatment group with triamcinolone dissolving microneedle patch,Control group with dissolving microneedle without triamcinolone
Sponsors
Division of Dermatology, Department of internal medicine, Faculty of medicine, Thammasat University
National Nanotechnology Center, National Science and Technology Development Agency
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Healthy male or female participants, aged 18-60. 2. Participants had hypertrophic scar or keloid more than 2 cm without any previous treatments, more than 6 months of intralesional steroids, or more than 3 months of light & laser treament. 3. Participants who are willing to join the project after receiving a detailed description of the project and signing a consent form for the study. 4. Participants can follow the testing method to follow up on treatment results throughout the study period and can report side effects that arise from the study immediately
Exclusion criteria
Exclusion criteria: 1. Participants who had history of treatment with intralesional steroids less than 6 months or light & laser treatment less than 3 months. 2. Participants who had a history of using systemic corticosteroids (oral, intramuscular, intravenous), chemotherapy, warfarin, heparin, or systemic retinoids 3. Participants who had active dermatitis or skin infection at the study site 4. Participants who are pregnant, breastfeeding or planning to become pregnant. 5. Participants who had a history of liver diseases, renal diseases. 6. Participants with any type of diabetes mellitus. 7.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Scar volume at day 0, 14-16, 28-30, 60 days skin imaging analysis ( Visioscan) | — |
Secondary
| Measure | Time frame |
|---|---|
| appearance of scar at day 0, 14-16, 28-30, 60 days Patient and observer scar assessment scale (POSAS),adverse effects at day 0, 14-16, 28-30, 60 days erythema, edema, burning and stinging, pustule, oozing/crusting,Histopathological change 60 day skin biopsy/ Imaging mass microscope | — |
Countries
Thailand
Contacts
Public ContactWareeporn Disphanurat
Division of Dermatology, Department of internal medicine, Faculty of medicine, Thammasat University, Thailand
Outcome results
None listed